Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver

Schneider, Günther; Maas, R.; Kool, Leo Schultze; Rummeny, Ernst J.; Gehl, Hans-Björn; Lodemann, Klaus‐Peter; Kirchin, Miles A.

doi:10.1097/00004424-200302000-00003

Cited by 102 publications

(61 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative studies in other indications have similarly highlighted the value of high-relaxivity gadobenate dimeglumine in permitting the use of lower doses. 21,22 As noted elsewhere, [23][24][25] the higher in vivo R1 relaxivity of gadobenate dimeglumine is due to weak, transient interaction of the gadobenate contrast- effective molecule with serum albumin, 26 which slows its molecular tumbling rate, leading to greater shortening of the T1 relaxation time and thus substantially increased signal intensity enhancement.…”

Section: Figmentioning

confidence: 77%

Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Figmentioning

confidence: 77%

Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…Gadobenate dimeglumine has been found useful for liver MRI. Because of its weak binding with serum albumin, this gadolinium-based contrast agent has twofold greater T1 relaxivity (9.7 L ⋅ mmol -1 ⋅ s -1 at 0.47 T) in human plasma than do other gadolinium-based agents [8,10,[13][14][15][16][17][18][19]. Gadobenate dimeglumine is a gadolinium-based paramagnetic contrast agent that combines the properties of a conventional, nonspecific, gadolinium-based agent with those of a liver-targeted agent, improving the rate of detection of focal hepatic lesions [8,18,20].…”

Section: Choi Et Almentioning

confidence: 99%

Hepatocellular Carcinoma in Liver Transplantation Candidates: Detection with Gadobenate Dimeglumine–Enhanced MRI

Choi

Lee

et al. 2008

American Journal of Roentgenology

View full text Add to dashboard Cite

529sis determines patient eligibility for and the potential success of curative treatments. Therefore, CT and MRI aided by technologic advances that afford improved spatial, temporal, and contrast resolution are regarded as promising alternative surveillance tools for detecting HCC [4,5]. Contrast-enhanced dynamic multiphasic imaging has substantial performance benefits because most HCCs are hypervascular lesions that typically become enhanced during the hepatic arterydominant phase of imaging [6]. OBJECTIVE. The purpose of this study was to retrospectively evaluate the diagnostic performance of dynamic gadobenate dimeglumine-enhanced MRI with explant pathologic correlation in the detection of hepatocellular carcinoma (HCC) in patients undergoing liver transplantation. Hepatocellular Carcinoma in H e p a t o b i l i a r y I m ag i ng • O r ig i n a l R e s e a rc hMATERIALS AND METHODS. Forty-seven patients (28 men, 19 women; mean age, 49 years) underwent dynamic gadobenate dimeglumine-enhanced MRI within 3 months before primary liver transplantation. Dynamic imaging was performed before (unenhanced) and after (hepatic arterial, portal venous, equilibrium, and 1-hour delayed phases) IV bolus administration of gadobenate dimeglumine at 0.1 mmol/kg body weight. Retrospective image analysis to detect HCC nodules was performed independently by two abdominal radiologists who had no pathologic information. On a per-nodule basis, the sensitivity and positive predictive value were calculated for the two observers. Sensitivity and specificity in the diagnosis of HCC also were evaluated. Fisher's exact test was performed to determine whether there was a detection difference between HCC nodules 1 cm in diameter or larger and nodules smaller than 1 cm and to evaluate the differences in causes of false-positive MRI findings based on lesion size (≥ 1 cm vs < 1 cm).RESULTS. Twenty-seven patients had 41 HCCs. In HCC detection, gadobenate dimeglumine-enhanced MRI had a sensitivity of 85% (35 of 41 HCCs) and a positive predictive value of 66% (35 of 53 readings) for observer 1 and a sensitivity of 80% (33 of 41 HCCs) and a positive predictive value of 65% (34 of 52 readings) for observer 2. For both observers, sensitivity in the detection of HCCs 1 cm in diameter and larger (91-94%) was significantly different (p < 0.05) from that in detection of HCCs smaller than 1 cm (29-43%). Nonneoplastic arterial hypervascular lesions more often caused false-positive diagnoses of lesions smaller than 1 cm in diameter (80-86%) on MR images than of those 1 cm in diameter and larger (0-25%). The difference was statistically significant (p < 0.05) for both observers. In diagnosis, gadobenate dimeglumine-enhanced MRI had a sensitivity of 87% (20 of 23 patients) and a specificity of 79% (19 of 24 patients) for both observers.CONCLUSION. Dynamic gadobenate dimeglumine-enhanced MRI has a sensitivity of 80-85% and a positive predictive value of 65-66% in the detection of HCC. The technique, however, is of limited value for detecting and characterizi...

show abstract

“…On the one hand, it is used as an extracellular agent for MRI similarly to Gd-DTPA, and on the other hand, it can be used in the liver to facilitate MRI detection and characterization of focal and diffuse hepatic diseases. [1][2][3][4] Gd-BOPTA is taken up into hepatocytes and excreted without biotransformation. 5,6 In rats, 50% of the dose injected is excreted into the bile, the remaining being excreted into urine.…”

mentioning

confidence: 99%

Gd-BOPTA Transport Into Rat Hepatocytes: Pharmacokinetic Analysis of Dynamic Magnetic Resonance Images Using a Hollow-Fiber Bioreactor

Planchamp

Gex‐Fabry²,

Dornier³

et al. 2004

Investigative Radiology

View full text Add to dashboard Cite

Rationale and Objectives:To investigate the transport of the hepatobiliary magnetic resonance (MR) imaging contrast agent Gd-BOPTA into rat hepatocytes. Materials and Methods:In a MR-compatible hollow-fiber bioreactor containing hepatocytes, MR signal intensity was measured over time during the perfusion of Gd-BOPTA. For comparison, the perfusion of an extracellular contrast agent (Gd-DTPA) was also studied. A compartmental pharmacokinetic model was developed to describe dynamic signal intensity-time curves. Results: The dynamic signal intensity-time curves of the hepatocyte hollow-fiber bioreactor during Gd-BOPTA perfusion were adequately fitted by 2 compartmental models. Modeling permitted to discriminate between the behaviors of the extracellular contrast agent (Gd-DTPA) and the hepatobiliary contrast agent (Gd-BOPTA). It allowed the successfully quantification of the parameters involved in such differences. Gd-BOPTA uptake was saturable at high substrate concentrations. Conclusions: The transport of Gd-BOPTA into rat hepatocytes was successfully described by compartmental analysis of the signal intensity recorded over time and supported the hypothesis of a transporter-mediated uptake.

show abstract

Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver

Abstract: The additional diagnostic information on delayed imaging, combined with the possibility to use a lower overall dose to obtain similar diagnostic information on dynamic imaging, offers a distinct clinical advantage for Gd-BOPTA for liver MRI.

Cited by 102 publications

References 28 publications

Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)

Multicenter, Intraindividual Comparison of Single-Dose Gadobenate Dimeglumine and Double-Dose Gadopentetate Dimeglumine for MR Angiography of the Supra-Aortic Arteries (the Supra-Aortic VALUE Study)

Hepatocellular Carcinoma in Liver Transplantation Candidates: Detection with Gadobenate Dimeglumine–Enhanced MRI

Gd-BOPTA Transport Into Rat Hepatocytes: Pharmacokinetic Analysis of Dynamic Magnetic Resonance Images Using a Hollow-Fiber Bioreactor

Contact Info

Product

Resources

About